Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW.

Leukemia. 2019 Nov 15. doi: 10.1038/s41375-019-0638-y. [Epub ahead of print]

PMID:
31732720
2.

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.

Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, Martinelli G, Petrie K, Zelent A, Böhmer FD, Groth M, Ernst T, Heidel FH, Scholl S, Hochhaus A, Schenk T.

Leukemia. 2019 Nov;33(11):2628-2639. doi: 10.1038/s41375-019-0581-y. Epub 2019 Oct 1.

PMID:
31576004
3.

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.

Perner F, Perner C, Ernst T, Heidel FH.

Cells. 2019 Aug 8;8(8). pii: E854. doi: 10.3390/cells8080854. Review.

4.

Plasma VCAM1 levels correlate with disease severity in Parkinson's disease.

Perner C, Perner F, Gaur N, Zimmermann S, Witte OW, Heidel FH, Grosskreutz J, Prell T.

J Neuroinflammation. 2019 May 8;16(1):94. doi: 10.1186/s12974-019-1482-8.

5.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L, Döhner K.

Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.

6.

Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.

Kresinsky A, Schnöder TM, Jacobsen ID, Rauner M, Hofbauer LC, Ast V, König R, Hoffmann B, Svensson CM, Figge MT, Hilger I, Heidel FH, Böhmer FD, Müller JP.

Oncogene. 2019 Jun;38(24):4773-4787. doi: 10.1038/s41388-019-0757-y. Epub 2019 Feb 28.

PMID:
30820040
7.

Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling.

Lowinus T, Heidel FH, Bose T, Nimmagadda SC, Schnöder T, Cammann C, Schmitz I, Seifert U, Fischer T, Schraven B, Bommhardt U.

Cell Commun Signal. 2019 Jan 16;17(1):5. doi: 10.1186/s12964-018-0317-z.

8.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M.

Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.

9.

Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging.

Kosan C, Heidel FH, Godmann M, Bierhoff H.

Cells. 2018 Nov 29;7(12). pii: E237. doi: 10.3390/cells7120237. Review.

10.

Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how.

Heidel FH, Ellis S.

Oncotarget. 2018 Oct 5;9(78):34642-34643. doi: 10.18632/oncotarget.26132. eCollection 2018 Oct 5. No abstract available.

11.

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.

Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1933-1944. doi: 10.1007/s00432-018-2724-3. Epub 2018 Aug 6.

PMID:
30083817
12.

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.

Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T; Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO).

Leukemia. 2018 Sep;32(9):2085-2087. doi: 10.1038/s41375-018-0214-x. Epub 2018 Jul 24. No abstract available.

PMID:
30042412
13.

JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller AJ, Fischer T.

J Clin Invest. 2018 Oct 1;128(10):4359-4371. doi: 10.1172/JCI90312. Epub 2018 Jul 19.

14.

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP.

Haematologica. 2018 Nov;103(11):e505-e509. doi: 10.3324/haematol.2017.185306. Epub 2018 Jun 7. No abstract available.

15.

Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients.

Perner C, Perner F, Stubendorff B, Förster M, Witte OW, Heidel FH, Prell T, Grosskreutz J.

J Neuroinflammation. 2018 Mar 28;15(1):99. doi: 10.1186/s12974-018-1135-3.

16.

Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018.

Heidel FH, Gale RP, Hochhaus A.

Leukemia. 2018 May;32(5):1055-1056. doi: 10.1038/s41375-018-0079-z. Epub 2018 Feb 27. No abstract available.

PMID:
29515237
17.

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH.

Leukemia. 2018 May;32(5):1211-1221. doi: 10.1038/s41375-018-0025-0. Epub 2018 Jan 30.

PMID:
29467485
18.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

19.

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.

Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.

20.

Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B.

Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4.

21.

Macrophage's little helper: vitamin A directs alternatively activated monocyte-derived macrophages to tissue-resident macrophages.

Schlüter D, Heidel FH.

Cell Mol Immunol. 2017 Oct;14(10):805-808. doi: 10.1038/cmi.2017.58. Epub 2017 Jul 10. No abstract available.

22.

Hacking the stem cell niche.

Lane SW, Heidel FH.

Blood. 2017 Jun 1;129(22):2951-2952. doi: 10.1182/blood-2017-04-777789. No abstract available.

PMID:
28572172
23.

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M.

Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.

PMID:
28512865
24.

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.

J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23.

PMID:
28233092
25.

JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH, Fischer T.

Leukemia. 2017 May;31(5):1223-1226. doi: 10.1038/leu.2017.26. Epub 2017 Jan 18. No abstract available.

26.

Chronic myelogenous leukemia evolving after treatment of multiple myeloma.

Wolleschak D, Heidel FH.

Blood. 2016 Jul 7;128(1):146. doi: 10.1182/blood-2016-03-706945. No abstract available.

PMID:
28092869
27.

Gain of function in Jak2V617F-positive T-cells.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.

Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. No abstract available.

PMID:
28074070
28.

RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC.

Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23.

29.

Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.

Perner F, Schnöder TM, Fischer T, Heidel FH.

Anticancer Res. 2016 Dec;36(12):6249-6258.

PMID:
27919943
30.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.

PMID:
27774990
31.

Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.

Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH.

J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9. doi: 10.1007/s00432-016-2209-1. Epub 2016 Jul 18.

PMID:
27431664
32.

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V.

Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.

33.

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.

Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19.

PMID:
26891877
34.

Leukemic mastopathy.

Schalk E, Heidel FH.

Int J Hematol. 2016 Apr;103(4):357-8. doi: 10.1007/s12185-016-1948-8. Epub 2016 Feb 8. No abstract available.

PMID:
26857154
35.

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH.

Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20. No abstract available.

36.

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH.

Leukemia. 2016 May;30(5):1220-1225. doi: 10.1038/leu.2015.292. Epub 2015 Oct 21. No abstract available.

37.

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD.

Leukemia. 2016 Feb;30(2):473-83. doi: 10.1038/leu.2015.234. Epub 2015 Aug 26.

PMID:
26308771
38.

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.

Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5. No abstract available.

PMID:
26242463
39.

Central Venous Catheter-Related Bloodstream Infections in Obese Hematologic Patients.

Schalk E, Färber J, Fischer T, Heidel FH.

Infect Control Hosp Epidemiol. 2015 Aug;36(8):995-6. doi: 10.1017/ice.2015.107. Epub 2015 May 20. No abstract available.

PMID:
25990462
40.

Prediction of central venous catheter-related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS).

Schalk E, Hanus L, Färber J, Fischer T, Heidel FH.

Ann Hematol. 2015 Sep;94(9):1451-6. doi: 10.1007/s00277-015-2387-y. Epub 2015 May 3.

PMID:
25933677
41.

Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity.

Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T.

Clin Cancer Res. 2015 Jan 15;21(2):240-8. doi: 10.1158/1078-0432.CCR-14-1436. Review.

42.

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW.

Cell Stem Cell. 2014 Dec 4;15(6):775-90. doi: 10.1016/j.stem.2014.11.010.

43.

Epo-induced erythroid maturation is dependent on Plcγ1 signaling.

Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T.

Cell Death Differ. 2015 Jun;22(6):974-85. doi: 10.1038/cdd.2014.186. Epub 2014 Nov 14.

44.

A rare cause of lower back pain.

Wolleschak D, Heidel FH.

Blood. 2014 Jul 10;124(2):165. No abstract available.

PMID:
25136733
45.

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.

Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24.

46.

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH.

Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. No abstract available.

47.

Germ and hematology: underlying disease influences diversity of germ spectra and antibiotic therapy.

Schalk E, Tammer I, Heidel FH.

Infect Control Hosp Epidemiol. 2014 Feb;35(2):208-10. doi: 10.1086/674864. No abstract available.

PMID:
24442091
48.

Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.

Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, Fischer T, Heidel FH.

J Hematol Oncol. 2013 Jun 11;6:39. doi: 10.1186/1756-8722-6-39. Review.

49.

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.

Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13.

50.

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.

Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA.

J Exp Med. 2013 Jan 14;210(1):15-22. doi: 10.1084/jem.20120596. Epub 2012 Dec 31.

Supplemental Content

Loading ...
Support Center